Toxicity of MRI and CT contrast agents

被引:3
|
作者
Hasebroock, Kendra M. [1 ]
Serkova, Natalie J. [1 ]
机构
[1] Univ Colorado, Anschutz Med Ctr, Canc Ctr Anim MRI PET CT Core, Dept Anesthesiol & Radiol, Aurora, CO 80045 USA
关键词
chronic kidney disease; contrast-induced nephropathy; CT estimated glomerular filtration rate; gadolinium; iodinated contrast agents; MRI; nephrogenic systemic fibrosis; NEPHROGENIC SYSTEMIC FIBROSIS; ENHANCED COMPUTED-TOMOGRAPHY; GLOMERULAR-FILTRATION-RATE; SQUAMOUS-CELL CARCINOMA; ALLERGIC-LIKE REACTIONS; CHRONIC KIDNEY-DISEASE; INDUCED NEPHROPATHY; LOW-OSMOLAR; EMISSION-TOMOGRAPHY; ADVERSE-REACTIONS;
D O I
10.1517/17425250902873796
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Anatomical and physiological imaging using CT and MRI are playing a critical role in patients' diagnosis, disease characterization and treatment planning. CT- and MRI-based protocols increasingly require an injection of iodinated CT and gadolinium (Gd)-based MRI contrast media. Although routinely used in clinical practice, iodinated and to a less extent Gd-based contrast media possess side effects: life-threatening contrast-induced nephropathy (CIN) is associated with CT and nephrogenic systemic fibrosis (NSF) with MRI contrast agents. CIN is defined as an acute decline in renal functions (serum creatinine increase > 0.5 mg/dl) after administration of iodinated contrast media. Patients with moderate-to-severe chronic kidney disease are considered the highest risk group for development of CIN. ON is more common with ionic high-osmolar contrast CT media. NSF is a rare condition characterized by the formation of connective tissue in the skin and systemically in the lung, liver, heart and kidney. Patients with end stage kidney disease, acute kidney injury and stage 4 - 5 chronic kidney disease are at a high risk for NSF The nonionic linear Gd-chelates are associated with the highest risk of NSF. This review summarizes the incidence, symptoms, safety profile of various CT and MRI contrast agents based on their physiochemical properties.
引用
收藏
页码:403 / 416
页数:14
相关论文
共 50 条
  • [1] Contrast agents for MRI
    Emily A. Waters
    Samuel A. Wickline
    Basic Research in Cardiology, 2008, 103 : 114 - 121
  • [2] Contrast agents for MRI
    Shokrollahi, H.
    MATERIALS SCIENCE AND ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS, 2013, 33 (08): : 4485 - 4497
  • [3] Contrast Agents in MRI
    Sobol, W. T.
    MEDICAL PHYSICS, 2008, 35 (06)
  • [4] Contrast agents for MRI
    Waters, Emily A.
    Wickline, Samuel A.
    BASIC RESEARCH IN CARDIOLOGY, 2008, 103 (02) : 114 - 121
  • [5] Safety of Administering Intravenous CT Contrast Agents Repeatedly or Using Both CT and MRI Contrast Agents on the Same Day: An Animal Study
    Bae, Heejin
    Oh, Hyewon
    Bin Park, Ga
    Chung, Yong Eun
    KOREAN JOURNAL OF RADIOLOGY, 2024, 25 (03) : 257 - 266
  • [6] Diffusion coefficients of articular cartilage for different CT and MRI contrast agents
    Kulmala, K. A. M.
    Korhonen, R. K.
    Julkunen, P.
    Jurvelin, J. S.
    Quinn, T. M.
    Kroger, H.
    Toyras, J.
    MEDICAL ENGINEERING & PHYSICS, 2010, 32 (08) : 878 - 882
  • [7] INOR 357-Carbon nanotube contrast agents for MRI and CT
    Moore, Valerie C.
    Joshi, Pratixa
    Conyers, Jodie L.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 36 - 36
  • [8] Uniform-sized oxide nanocrystals for contrast agents for MRI and CT
    Hyeon, Taeghwan
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
  • [9] OVERVIEW OF MRI CONTRAST AGENTS
    DUROUX, M
    RADIOLOGE, 1995, 35 (11): : S247 - S248
  • [10] METALLOPORPHYRIN CONTRAST AGENTS FOR MRI
    FIEL, RJ
    MAZURCHUK, R
    BUTTON, T
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1988, 196 : 15 - INOR